aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective […]
StockNews.com assumed coverage on shares of aTyr Pharma (NASDAQ:LIFE – Get Rating) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock. Several other equities analysts have also weighed in on the company. Roth Capital reissued a buy rating on shares of aTyr Pharma in a report on […]
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 299,200 shares, a decrease of 25.1% from the April 15th total of 399,500 shares. Based on an average trading volume of 560,900 shares, the […]
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 299,200 shares, a decrease of 25.1% from the April 15th total of 399,500 shares. Based on an average trading volume of 560,900 shares, the short-interest ratio is […]
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) was the recipient of a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 299,200 shares, a decline of 25.1% from the April 15th total of 399,500 shares. Based on an average daily volume of 560,900 shares, the […]